Elevance Health (ELV) Projected to Post Quarterly Earnings on Wednesday
by Scott Moore · The Cerbat GemElevance Health (NYSE:ELV – Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Wednesday, April 22nd. Analysts expect the company to announce earnings of $10.74 per share and revenue of $48.2140 billion for the quarter. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, April 22, 2026 at 8:30 AM ET.
Elevance Health (NYSE:ELV – Get Free Report) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company posted $3.84 EPS. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.
Elevance Health Price Performance
Shares of NYSE:ELV opened at $323.02 on Monday. The stock has a market cap of $70.96 billion, a PE ratio of 12.86, a PEG ratio of 1.78 and a beta of 0.49. The company’s fifty day moving average is $308.99 and its 200 day moving average is $331.91. Elevance Health has a 52 week low of $273.71 and a 52 week high of $432.93. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.
Elevance Health Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th were given a $1.72 dividend. The ex-dividend date was Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.1%. Elevance Health’s dividend payout ratio is presently 27.39%.
Institutional Investors Weigh In On Elevance Health
A number of institutional investors have recently made changes to their positions in the company. Pettinga Financial Advisors LLC grew its holdings in shares of Elevance Health by 4.8% during the fourth quarter. Pettinga Financial Advisors LLC now owns 812 shares of the company’s stock valued at $285,000 after buying an additional 37 shares during the last quarter. Foresight Global Investors Inc. grew its holdings in shares of Elevance Health by 5.6% during the fourth quarter. Foresight Global Investors Inc. now owns 865 shares of the company’s stock valued at $303,000 after buying an additional 46 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Elevance Health by 2.6% during the fourth quarter. UMB Bank n.a. now owns 2,113 shares of the company’s stock valued at $741,000 after buying an additional 53 shares during the last quarter. HM Payson & Co. grew its holdings in shares of Elevance Health by 15.0% during the fourth quarter. HM Payson & Co. now owns 437 shares of the company’s stock valued at $153,000 after buying an additional 57 shares during the last quarter. Finally, CreativeOne Wealth LLC grew its holdings in shares of Elevance Health by 4.4% during the third quarter. CreativeOne Wealth LLC now owns 1,569 shares of the company’s stock valued at $507,000 after buying an additional 66 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Analyst Ratings Changes
Several brokerages recently issued reports on ELV. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the company an “outperform” rating in a research report on Thursday, January 8th. Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a research report on Tuesday, February 3rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $332.00 price target on shares of Elevance Health in a research report on Thursday, January 29th. Truist Financial reduced their price target on shares of Elevance Health from $390.00 to $375.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Finally, Robert W. Baird reduced their price target on shares of Elevance Health from $340.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Twelve equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elevance Health has a consensus rating of “Hold” and a consensus target price of $383.57.
View Our Latest Stock Report on ELV
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.